# Treatment of Hemophilia A Patients With FVIII Inhibitors

> **NCT04023019** · — · RECRUITING · sponsor: **Emory University** · enrollment: 120 (estimated)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Nuwiq
- **BIOLOGICAL:** Octanate
- **BIOLOGICAL:** Wilate
- **BIOLOGICAL:** Emicizumab
- **BIOLOGICAL:** Recombinant factor VIIa (rFVIIa)
- **BIOLOGICAL:** Activated prothrombin complex concentrate (aPCC)

## Key facts

- **NCT ID:** NCT04023019
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-17
- **Primary completion:** 2028-12
- **Final completion:** 2029-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04023019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04023019, "Treatment of Hemophilia A Patients With FVIII Inhibitors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04023019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*